The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

North America held the largest cancer tumor profiling market share, and Asia-Pacific was the fastest-growing region in 2022.

The global cancer tumor profiling market is expected to grow from $9.62 billion in 2022 to $11.12 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The cancer tumor profiling market size is expected to grow to $18.18 billion in 2027 at a CAGR of 13.1%.

Major Driver In The Cancer Tumor Profiling Market ­– Increase In The Incidences Of Cancer Across The Globe
For example, the World Health Organisation (WHO) predicts a 19.3 million rise in cancer cases by 2020, with over 10 million deaths worldwide. Lung and breast cancer accounted for 23.1% of all cancer diagnoses among these new cases. Furthermore, 1 in 5 people may develop cancer during their lifetime, and 1 in 11 women and 1 in 8 men will die from it, according to the International Agency for Research on Cancer (IARC). As a result, rising cancer incidences around the world drive the growth of the cancer and tumour profiling market.

View More On The Cancer Tumor Profiling Market Report 2023 – https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Key Cancer Tumor Profiling Market Segments
1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies
3) By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Other Types
4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

Recent Cancer Tumor Profiling Market Trend – Research And Development Activities
Major cancer and tumour profiling firms are focusing on research and development to suit consumer demand and strengthen their position. For example, QIAGEN N.V, a German company that develops sample and assay technology for applied testing, pharmaceutical development, molecular diagnostics, and academic research, announced in February 2020 the Conformitè Europenne (CE)-marking and commercialization of therascreen PIK3CA RGQ PCR Kit in Europe as a tool to help identify breast cancer patients with PIK3CA mutations. Therascreen PIK3CA is a diagnostic assay for detecting an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and it is the first to allow testing of DNA from plasma specimens or FFPE tissue.

Cancer Tumor Profiling Market Prominent Players
Major players in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString, NeoGenomics Laboratories, Lucence Health Inc., ACT Genomics Co. Ltd., Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation (Genomic Health Inc.), Guardant Health, and Foundation Medicine Inc.

Request A Sample Of The Global Cancer Tumor Profiling Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

The Cancer Tumor Profiling Global Market Report 2023  provides a comprehensive overview on the cancer tumor profiling market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Cancer tumour profiling is a laboratory test that looks for specific genes, gene mutations (changes), proteins, or other indicators in tumour tissue. Tumour profiling can aid in treatment planning by predicting whether cancer will recur or spread to other regions of the body.

View More Related Reports –
Cancer Biologics Global Market Report 2023
Cancer Diagnostics Global Market Report 2023
Tumor Ablation Therapy Devices Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model